UNSPSC 51341807: Daclatasvir

Antiviral for the treatment of Hepatitis C virus infections

UNSPSC 51341807 Daclatasvir, a Commodity code, nominally designates hepatitis C antivirals but shows limited direct relevance to recent state and local procurement activity. The recent opportunities tagged under this code involve naloxone and drug deactivation systems, medical and first aid supplies for emergency response, generic pharmaceuticals and OTC products through cooperative purchasing, and direct-to-manufacturer prescription programs—none of which align with daclatasvir's specific therapeutic classification. State and local governments accessing pharmaceutical supply through this code appear to do so primarily via health agencies, fire departments, cooperative purchasing alliances, and state health and human services commissions procuring broader classes of medical products, emergency supplies, and pharmacy benefit management solutions rather than specialized antivirals.

Geographic activity in recent opportunities spans Florida (Seminole County), Texas (Health and Human Services Commission), Minnesota (MMCAP cooperative purchasing serving multiple states including Oregon), and Florida again (City of Tampa), indicating dispersed but limited current sourcing under this code's nominal designation. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP (S1070000015802, due March 26, 2026) established multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities; the City of Tampa's IFB 26P00145 (due March 13, 2026) sought medical and first aid supplies for the Tampa Fire Department Rescue Division with an estimated contract value of $700,000, designated as sheltered for Small Local Business Enterprises with a 5 percent bid discount; and Seminole County's IFB 60459723LAS (due July 26, 2023) procured 1,900 units of naloxone and 800 safe drug deactivation systems annually. The Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) gathered vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The code shows little targeted activity for daclatasvir procurement specifically and substantial mismatch between its nominal scope and what jurisdictions are actually buying under it.